Evaluation of Platelet Aggregability in Patients with Takayasu's Arteritis

Key facts

Sponsor

Jose Carlos Nicolau

Intervention

Clopidogrel(drug)

Enrollment

100 enrolled

Eligibility

18 years · All sexes

Timeline

2024 – 2027

Study locations (1)

• Heart Institute (InCor) / University of São Paulo, São Paulo, São Paulo, São Paulo, Brazil

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Takayasu arteritis

Additional recruiting or active studies for the same condition.

• RECRUITINGNCT07351422
  Investigating Management, Perspectives and Attitudes Towards Care in Takayasu Arteritis
  University of Edinburgh
• RECRUITINGNCT07276087
  Physical and Psychosocial Parameters in Takayasu Arteritis and Behçet's Disease: A Comparative Study With Healthy Controls
  ÖZLEM NUR TOK YAMAN
• RECRUITINGNANCT07491913
  Biologic Treatment Withdrawal in Takayasu Arteritis Patients in Sustained Remission
  Marmara University
• RECRUITINGPHASE4NCT06498089
  A Randomized, Controlled, Open-label, Multicenter Clinical Trial Comparing the Efficacy and Safety of a Precision Treatment Regimen Based on Clinical-molecular Phenotypes with a Conventional Treatment Regimen in the Treatment of Patients with Active Takayasu's Arteritis
  Shanghai Zhongshan Hospital
• RECRUITINGNANCT06178419
  Remote Ischemic Conditioning for Cerebral Ischemia in Patients With Takayasu Arteritis (TARIC-1)
  Xuanwu Hospital, Beijing
• RECRUITINGPHASE4NCT05102448
  Comparison of Tofacitinib and Methotrexate in Takayasu's Arteritis
  Shanghai Zhongshan Hospital
• RECRUITINGPHASE4NCT04300686
  A Pilot Study in Severe Patients With Takayasu Arteritis.
  Shanghai Zhongshan Hospital
• ACTIVE NOT RECRUITINGPHASE3NCT04161898
  A Study to Evaluate the Efficacy and Safety of Upadacitinib in Participants With Takayasu Arteritis (TAK)
  AbbVie

See all trials for Takayasu arteritis →